Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

Annals of Neurology

Volumn 39, Issue 5, 1996, Pages 574-578

  Papa, Stella M ^a   Chase, Thomas N ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; ISOQUINOLINE DERIVATIVE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; BENSERAZIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL; ANIMAL BEHAVIOR; ARTICLE; CHEMICALLY INDUCED DISORDER; CHOREA; DRUG ANTAGONISM; DRUG EFFECT; DYSKINESIA; DYSTONIA; FEMALE; MACACA; MALE; PARKINSON DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG POTENTIATION; MONKEY; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; CHOREA; DYSKINESIA, DRUG-INDUCED; DYSTONIA; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; ISOQUINOLINES; LEVODOPA; MACACA FASCICULARIS; MACACA MULATTA; MALE; PARKINSON DISEASE, SECONDARY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0029665122     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410390505     Document Type: Article

References (20)

1. Marsden CD, Parkes JD, Quinn N. Fluctuation of disability in Parkinson's disease clinical aspects. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworths Scientific, 1982:96-122
2. Bravi D, Mouradian MM, Roberts JW, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994;36:27-31
3. Engber TM, Susel Z, Kuo S, et al. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991;552:113-118
4. Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology 1993;42(12 suppl 6):S23-S27
5. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432
6. Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 1994;662:69-74
7. Albin RL, Makowiec ZR, Hollingsworth LS, et al. Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience 1992;46:35-48
8. Greenamyre JT. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J Neural Transm Gen Sect 1993;91:255-269
9. Klockgether T, Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 1990;28:539-546
10. Greenamyre JT, Eller RV, Zhang Z, et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 1994;35:655-661
11. Engber TM, Papa SM, Boldly RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 1994;5:2586-2588
12. Schoepp DD, Ornstein PL, Salhoff CR, Leander JD. Neuroprotectant effects of LY274614, a structurally novel systemically active competitive NMDA receptor antagonist. J Neural Transm Gen Sect 1991;85:131-143
13. Papa SM, Boldry RC, Engber TM, et al. Reversal of levodopa induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 1995;701:13-18
14. Rupniak NMJ, Boyce S, Steventon MJ, et al. Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys. Ann Neurol 1992;32:103-105
15. Kotter R. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog Neurobiol 1994;44:163-196
16. Dogali M, Fazzini E, Kolodny E, et al. Stereotactic ventral pallidotomy for Parkinson's disease. Neurology 1995;45:753-761
17. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990;249:1436-1438
18. Blanchet PJ, Verhagen-Metman L, Mouradian MM, Chase TN. Symptomatic effects of N-methyl-D-aspartate (NMDA) receptor antagonism in Parkinson's disease. Move Disord (in press)
19. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992;31:119-130
20. Standaert DG, Testa CM, Young AB, Penney JB Jr. Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J Comp Neurol 1994;343: 1-16